Efaproxiral (sodium)

Efaproxiral sodium (RSR13 sodium) is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy. in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT.

Product Specifications

CAS Number

[170787-99-2]

Product Name Alternative

RSR13 (sodium)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Efaproxiral-sodium.html

Purity

99.72

Solubility

DMSO : 175 mg/mL (ultrasonic) |H2O : ≥ 33.33 mg/mL

Smiles

CC(C)(OC1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1)C(O[Na])=O

Molecular Formula

C20H22NNaO4

Molecular Weight

363.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94 (12) :1777-1784.